Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.

Oded ShamrizElchanan ParnasaLimor RubinAviv TalmonYaarit RibakEyal LebelVladimir VainsteinShlomzion AumannRevital SabanMoshe E GattYuval Tal

Published in: European journal of haematology (2022)

Desensitization to lenalidomide is safe and effective. Discontinuation of lenalidomide in MM patients with delayed hypersensitivity and no contraindication to desensitization should be discouraged. Collaboration between hematologists and allergists is needed.

Keyphrases

multiple myeloma
drug induced
newly diagnosed
randomized controlled trial
high glucose
stem cell transplantation
chronic lymphocytic leukemia
oxidative stress
replacement therapy